Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2001 Aug;45(8):2372-4.
doi: 10.1128/AAC.45.8.2372-2374.2001.

In vitro activities of MK-0826 and 16 other antimicrobials against Bacteroides fragilis group strains

C Betriu  1 , A Sánchez, M L Palau, M Gómez, J J Picazo
Affiliations
Comparative Study

In vitro activities of MK-0826 and 16 other antimicrobials against Bacteroides fragilis group strains

C Betriu et al. Antimicrob Agents Chemother. 2001 Aug.

Abstract

The activity of MK-0826, a new carbapenem, against 309 Bacteroides fragilis group strains was investigated and compared with that of 11 other beta-lactam and 5 non-beta-lactam agents. MK-0826 showed excellent activity (MICs ranged from < or =0.06 to 4 microg/ml). The new carbapenem may be useful in the treatment of mixed anaerobic infections involving B. fragilis group strains.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

    1. Aldridge K E, Gelfand M, Reller L B, Ayers L W, Pierson C L, Schoenknecht F, Tilton R C, Wilkins J, Henderberg A, Schiro D D, Johnson M, Janney A, Sanders C V. A five-year multicenter study of the susceptibility of the Bacteroides fragilis group isolates to cephalosporins, cephamicins, penicillins, clindamycin, and metronidazole in the United States. Diagn Microbiol Infect Dis. 1994;18:235–241. - PubMed
    1. Aldridge K E, Ashcraft D, Cambre K, Pierson C L, Jenkins S G, Rosenblatt J E. Multicenter survey of the changing in vitro antimicrobial susceptibilities of clinical isolates of Bacteroides fragilis group, Prevotella, Fusobacterium, Porphyromonas, and Peptostreptococcus species. Antimicrob Agents Chemother. 2001;45:1238–1243. - PMC - PubMed
    1. Bandoh K, Ueno K, Watanabe K, Nato K. Susceptibility patterns and resistance to imipenem in the Bacteroides fragilis group species in Japan: a 4-year study. Clin Infect Dis. 1993;16(Suppl. 4):S382–S386. - PubMed
    1. Betriu C, Cabronero C, Gómez M, Picazo J J. Changes in the susceptibility of Bacteroides fragilis group organisms to various antimicrobial agents. Eur J Clin Microbiol Infect Dis. 1992;11:352–356. - PubMed
    1. Betriu C, Gómez M, Palau M L, Sánchez A, Picazo J J. Activities of new antimicrobial agents (trovafloxacin, moxifloxacin, sanfetrinem, and quinupristin-dalfopristin) against Bacteroides fragilis group: Comparison with the activities of 14 other agents. Antimicrob Agents Chemother. 1999;43:2320–2322. - PMC - PubMed

Publication types

MeSH terms

LinkOut - more resources